Brookfield is taking the next step in its streamlining process.
Pfizer Inc. today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® ...
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a broader FDA label in metastatic castration-resistant prostate cancer, ...
It may sound too bizarre to be true, but the Amazon molly (Poecilia formosa), a fish that inhabits rivers, lakes, and swamps ...
First regimen to be approved in India to demonstrate superiority to platinum-containing chemotherapy, the current standard of care for adult patients with unresectable or metastatic urothelial cance ...
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced new data to be presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29 ...
Additional research highlights integration of BluePrint molecular subtyping and ImPrint immune profiling to optimize prediction of neoadjuvant treatment response in HER2-positive early-stage breast ...
A new study locates the brain's symbolic engine for compositional generalization within the ventral premotor cortex.
Morning Overview on MSN
Cancer’s most notorious protein MYC quietly repairs the DNA damage chemo inflicts — block that trick and treatment could hit tumor cells far harder
Chemotherapy drugs like doxorubicin and etoposide work by snapping a cancer cell’s DNA in two. The breaks are supposed to be ...
First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline –– Announced FDA Approval of VEPPANU™ ...
It may sound too bizarre to be true but the Amazon molly (Poecilia formosa), a fish that inhabits rivers, lakes and swamps in Mexico and Texas, exists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results